Durable clinical benefit with nivolumab plus low-dose ipilimumab as first-line in microsatellite instability ?high/mismatch repair deficient metastatic colorectal cancer.
Heinz-Josef J. Lenz, et al.
演題レポート
Proffered Paper Session
#LBA19
大腸癌
Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from cohort 2 of MODUL ? a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy.
Axel Grothey, et al.
#LBA20
大腸癌
TRIBE2: a phase III, randomized strategy study by GONO in the 1st- and 2nd-line treatment of unresectable metastatic colorectal cancer (mCRC) patients (pts).
Chiara Cremolini, et al.
#LBA25
胃癌
TAGS: a phase 3, randomised, double-blind study of trifluridine/tipiracil (TAS-102) versus placebo in patients with refractory metastatic gastric cancer.
Hendrik-Tobias Arkenau, et al.
#LBA26
肝細胞癌
Updated safety and clinical activity results from a Phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC).
Michael J. Pishvaian, et al.
#LBA27
肝細胞癌
A randomized multicentered phase 2 study to evaluate SHR-1210 (PD-1 antibody) in subjects with advanced hepatocellular carcinoma (HCC) who failed or intolerable to prior systemic treatment.
Shu K. Qin, et al.
#50O
がん全般
Plasma cell-free DNA (cfDNA) assays for early multi-cancer detection: the circulating cell-free genome atlas (CCGA) study.
Minetta C. Liu, et al.
#615O
胆道癌
Randomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA).
Daisuke Sakai, et al.
Poster Discussion Session
#LBA28
胆道癌
Updated results from a phase II study of infigratinib （BGJ398）, a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions.
Milind Jovle, et al.
#453PD
大腸癌
Efficacy and quality of life in VOLFI trial: mFOLFOXIRI + Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer (mCRC): a randomized phase II trial of the AIO (AIO-KRK-0109).
Michael Geissler, et al.
#454PD
大腸癌
Influence of treatment with prior bevacizumab: A combined analysis of individual patient data from ASPECCT and WJOG6510G trial which compared panitumumab versus cetuximab in patients with wild-type KRAS exon2 metastatic colorectal cancer.
Hiroya Taniguchi, et al.
#617PD
胃癌および胃食道接合部癌
A phase 3 study of nivolumab (Nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Two-years update data.
Taroh Sato, et al.
#620PD
食道癌
Enteral nutrition improves nutritional status, treatment tolerance and outcomes in patients with esophageal cancer undergoing concurrent chemoradiotherapy: results of a prospective, randomized, controlled, multicenter trial (NCT02399306).
Tao Li, et al.
Poster Display Session
#467P
大腸癌
Prospective evaluation of regorafenib dose escalation strategy with low starting dose in patients with colorectal cancer.
Toshiki Masuishi, et al.
#563P
大腸癌
Updated results of phase 1 study of trastuzumab deruxtecan (DS-8201a) in HER2-expressing advanced colorectal cancer.
Takayuki Yoshino, et al.
#667P＋668P
胃癌
A phase II study of Trastuzumab with S-1 plus Oxaliplatin for HER2-positive advanced gastric cancer (HIGHSOX).
Keisho Chin, et al.
Updated analysis of a phase II study of SOX plus trastuzumab for the patients with HER2 positive advanced or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS1501B.
Satoshi Yuki, et al.
by European Society for Medical Oncology
by European Society for Medical Oncology
by European Society for Medical Oncology
by European Society for Medical Oncology